Advertisement

Cancer Causes & Control

, Volume 24, Issue 5, pp 961–977 | Cite as

Do diagnostic and treatment delays for colorectal cancer increase risk of death?

  • Sandi L. Pruitt
  • Amy Jo Harzke
  • Nicholas O. Davidson
  • Mario Schootman
Original paper

Abstract

Background

Using 1998–2005 SEER-Medicare data, we examined the effect of diagnostic and treatment delays on all-cause and colorectal cancer (CRC)-specific death among US adults aged ≥ 66 years with invasive colon or rectal cancer. We hypothesized that longer delays would be associated with a greater risk of death.

Methods

We defined diagnostic and treatment delays, respectively, as days between (1) initial medical consult for CRC symptoms and pathologically confirmed diagnosis (maximum: 365 days) and (2) pathologically confirmed diagnosis and treatment (maximum: 120 days). Cases (CRC deaths) and controls (deaths due to other causes or censored) were matched on survival time. Logistic regression analyses adjusted for sociodemographic, tumor, and treatment factors.

Results

Median diagnostic delays were 60 (colon) and 40 (rectal) days and treatment delays were 13 (colon) and 16 (rectal) days in 10,663 patients. Colon cancer patients with the longest diagnostic delays (8–12 months vs. 14–59 days) had higher odds of all-cause (aOR: 1.31 CI: 1.08–1.58), but not CRC-specific death. Colon cancer patients with the shortest treatment delays (<1 vs. 1–2 weeks) had higher odds of all-cause (aOR: 1.23 CI: 1.01–1.49), but not CRC-specific death. Among rectal cancer patients, delays were not associated with risk of all-cause or CRC-specific death.

Conclusions

Longer delays of up to 1 year after symptom onset and 120 days for treatment did not increase odds of CRC-specific death. There may be little clinical benefit in detecting and treating existing symptomatic disease earlier. Screening prior to symptom onset must remain the primary goal to reduce CRC incidence, morbidity, and mortality.

Keywords

Colorectal cancer Delayed diagnosis Time factors Outcomes Survival SEER-medicare 

Notes

Acknowledgments

We gratefully acknowledge James Struthers for his data management and programming services. We thank Margie Olsen, PhD and Jean Wang, MD for their assistance and helpful advice and Leah Akers and Chris Davenport for their help with medical coding. We also thank the Center for Administrative Data Research of the Institute of Clinical and Translational Sciences and the Alvin J. Siteman Cancer’s Health Behavior, Communications, and Outreach Core at the Washington University School of Medicine. This work was supported by grants from the National Cancer Institute (CA112159); the National Center for Research Resources Washington University-ICTS (KL2 RR024994); and the Health Behavior, Communication and Outreach Core; the Core is supported in part by the National Cancer Institute Cancer Center Support Grant (P30 CA91842) to the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri. NOD was supported by grants DK-56260, HL-38180, and DDRCC DK-52574. This study used the linked SEER-Medicare database. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. Contents of this paper are solely the responsibility of the authors and do not necessarily represent the official view of the NIH.

Supplementary material

10552_2013_172_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 19 kb)

References

  1. 1.
    American Cancer Society Cancer Facts and Figures (2012) http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed on 27 July 2012
  2. 2.
    Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328(19):1365–1371PubMedCrossRefGoogle Scholar
  3. 3.
    Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS (1992) A case–control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326(10):653–657PubMedCrossRefGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention (CDC) (2011) Vital signs: colorectal cancer screening, incidence, and mortality—United States, 2002–2010. MMWR Morb Mortal Wkly Rep 60(26):884–889Google Scholar
  5. 5.
    Neal RD (2009) Do diagnostic delays in cancer matter? Br J Cancer 101(Suppl 2):S9–S12PubMedCrossRefGoogle Scholar
  6. 6.
    Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguilo A (2007) Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: a review. Eur J Cancer 43(17):2467–2478PubMedCrossRefGoogle Scholar
  7. 7.
    Ramos M, Esteva M, Cabeza E, Llobera J, Ruiz A (2008) Lack of association between diagnostic and therapeutic delay and stage of colorectal cancer. Eur J Cancer 44(4):510–521PubMedCrossRefGoogle Scholar
  8. 8.
    Terhaar sive Droste JS, Oort FA, van der Hulst RW, Coupe VM, Craanen ME, Meijer GA, Morsink LM, Visser O, van Wanrooij RL, Mulder CJ (2010) Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study. BMC Cancer 10:332Google Scholar
  9. 9.
    Fisher DA, Zullig LL, Grambow SC, Abbott DH, Sandler RS, Fletcher RH, El-Serag HB, Provenzale D (2010) Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System. Dig Dis Sci 55(5):1434–1441PubMedCrossRefGoogle Scholar
  10. 10.
    Torring ML, Frydenberg M, Hamilton W, Hansen RP, Lautrup MD, Vedsted P (2012) Diagnostic interval and mortality in colorectal cancer: U-shaped association demonstrated for three different datasets. J Clin Epidemiol 65(6):669–678PubMedCrossRefGoogle Scholar
  11. 11.
    Torring ML, Frydenberg M, Hansen RP, Olesen F, Hamilton W, Vedsted P (2011) Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care. Br J Cancer 104(6):934–940PubMedCrossRefGoogle Scholar
  12. 12.
    Iversen LH, Antonsen S, Laurberg S, Lautrup MD (2009) Therapeutic delay reduces survival of rectal cancer but not of colonic cancer. Br J Surg 96(10):1183–1189. doi: 10.1002/bjs.6700 PubMedCrossRefGoogle Scholar
  13. 13.
    Jullumstro E, Lydersen S, Moller B, Dahl O, Edna TH (2009) Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer. Eur J Cancer 45(13):2383–2390PubMedCrossRefGoogle Scholar
  14. 14.
    Simunovic M, Rempel E, Theriault ME, Baxter NN, Virnig BA, Meropol NJ, Levine MN (2009) Influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival. Can J Surg 52(4):E79–E86PubMedGoogle Scholar
  15. 15.
    Wattacheril J, Kramer JR, Richardson P, Havemann BD, Green LK, Le A, El-Serag HB (2008) Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Aliment Pharmacol Ther 28(9):1166–1174PubMedCrossRefGoogle Scholar
  16. 16.
    Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, Winchester DP, Bentrem DJ (2011) Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg 253(4):779–785PubMedCrossRefGoogle Scholar
  17. 17.
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8):IV-3-18Google Scholar
  18. 18.
    Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BKe (eds)SEER cancer statistics review, 1975–2007, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010
  19. 19.
    Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26(23):3860–3866PubMedCrossRefGoogle Scholar
  20. 20.
    Coates AS (1999) Breast cancer: delays, dilemmas, and delusions. Lancet 353(9159):1112–1113PubMedCrossRefGoogle Scholar
  21. 21.
    Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD (1999) The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer 79(5–6):858–864PubMedCrossRefGoogle Scholar
  22. 22.
    Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ (1999) Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 353(9159):1119–1126PubMedCrossRefGoogle Scholar
  23. 23.
    Porter MP (2010) Examining the association between delay in diagnosis and decreased survival in bladder cancer. Cancer 116(22):5122–5125PubMedCrossRefGoogle Scholar
  24. 24.
    Ray WA (2005) Observational studies of drugs and mortality. N Engl J Med 353(22):2319–2321PubMedCrossRefGoogle Scholar
  25. 25.
    Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16(3):241–249PubMedCrossRefGoogle Scholar
  26. 26.
    Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167(4):492–499PubMedCrossRefGoogle Scholar
  27. 27.
    Jung SY, Sereika SM, Linkov F, Brufsky A, Weissfeld JL, Rosenzweig M (2011) The effect of delays in treatment for breast cancer metastasis on survival. Breast Cancer Res Treat 130(3):953–964PubMedCrossRefGoogle Scholar
  28. 28.
    Hu C, Xing Y, Cormier JN, Chang GJ (2009) The validity of cause of death coding within the Surveillance, Epidemiology, and End Results (SEER) Registry. J Clin Oncol 27(15s):6544Google Scholar
  29. 29.
    Lund JL, Harlan LC, Yabroff KR, Warren JL (2010) Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease. Cancer Invest 28(7):758–764PubMedCrossRefGoogle Scholar
  30. 30.
    Maguire A, Porta M, Malats N, Gallen M, Pinol JL, Fernandez E (1994) Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function. ISDS II Project Investigators. Eur J Cancer 30A(6):785–792PubMedCrossRefGoogle Scholar
  31. 31.
    Taylor M, Turner D, Latosinsky S, Noseworthy T (2005) Determining acceptable waiting times for the surgical treatment of solid organ malignancies—a systematic review. http://www.cancercare.mb.ca/cancercare_resources/EPI/pdfs/CIHR_WaitTime_Report2_111005.pdf. Accessed 17 Nov 2011. Toward Canadian benchmarks for health services wait times? Evidence, application and research priorities (Report 2)
  32. 32.
    Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P (2008) Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut 57(11):1545–1553PubMedCrossRefGoogle Scholar
  33. 33.
    Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ, de Vet HC Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. BMJ 340:c1269Google Scholar
  34. 34.
    El-Serag HB, Petersen L, Hampel H, Richardson P, Cooper G (2006) The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. Arch Intern Med 166(20):2202–2208PubMedCrossRefGoogle Scholar
  35. 35.
    Fisher DA, Grubber JM, Castor JM Coffman CJ (2010) Ascertainment of colonoscopy indication using administrative data. Dig Dis Sci 55(6):1721–1725Google Scholar
  36. 36.
    American Medical Association (2001) Physicians’ current procedural terminology CPT 2002. American Medical Association, ChicagoGoogle Scholar
  37. 37.
    Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML (2008) Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100(12):888–897PubMedCrossRefGoogle Scholar
  38. 38.
    Hodgson DC, Fuchs CS, Ayanian JZ (2001) Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 93(7):501–515PubMedCrossRefGoogle Scholar
  39. 39.
    Polite BN, Dignam JJ, Olopade OI (2006) Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 24(14):2179–2187PubMedCrossRefGoogle Scholar
  40. 40.
    Schenck AP, Klabunde CN, Warren JL, Peacock S, Davis WW, Hawley ST, Pignone M, Ransohoff DF (2007) Data sources for measuring colorectal endoscopy use among Medicare enrollees. Cancer Epidemiol Biomarkers Prev 16(10):2118–2127PubMedCrossRefGoogle Scholar
  41. 41.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRefGoogle Scholar
  42. 42.
    National Cancer Institute SEER-Medicare: Calculation of comorbidity weights. http://healthservices.cancer.gov/seermedicare/program/comorbidity.html. Accessed on 18 July 2011
  43. 43.
    Parchman ML, Culler SD (1999) Preventable hospitalizations in primary care shortage areas. An analysis of vulnerable Medicare beneficiaries. Arch Fam Med 8(6):487–491PubMedCrossRefGoogle Scholar
  44. 44.
    Iacus SM, King G, Porro G (2011) Multivariate matching methods that are monotonic imbalance bounding. Avail at http://gking.harvard.edu/files/abs/cem-math-abs.shtml. J Am Stat Assoc 106:345–361Google Scholar
  45. 45.
    Iacus SM, King G, Porro G (2011) Causal inference without balance checking: coarsened exact matching. Avail at http://gking.harvard.edu/files/abs/cem-plus-abs.shtml
  46. 46.
    Institute of Medicine Crossing the quality chasm: a new health system for the 21st century. National Academy Press, Washington, DC. Available at http://books.nap.edu/catalog.php?record_id=10027
  47. 47.
    Patwardhan MB, Samsa GP, McCrory DC, Fisher DA, Mantyh CR, Morse MA, Prosnitz RG, Cline KE, Gray RN (2006) Cancer care quality measures: diagnosis and treatment of colorectal cancer. Evidence report/technology assessment no. 138. (Prepared by the Duke Evidence based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 06-E002. Agency for Healthcare Research and Quality, Rockville, MDGoogle Scholar
  48. 48.
    Department of Health (2000) Referral guidelines for suspected cancer. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4014421.pdf. Accessed 30 Nov 2011
  49. 49.
    Department of Health The NHS cancer plan. http://www.thh.nhs.uk/documents/_Departments/Cancer/NHSCancerPlan.pdf Accessed 29 Nov 2011
  50. 50.
    Korsgaard M, Pedersen L, Sorensen HT, Laurberg S (2006) Reported symptoms, diagnostic delay and stage of colorectal cancer: a population-based study in Denmark. Colorectal Dis 8(8):688–695PubMedCrossRefGoogle Scholar
  51. 51.
    Singh H, De Coster C, Shu E, Fradette K, Latosinsky S, Pitz M, Cheang M, Turner D (2010) Wait times from presentation to treatment for colorectal cancer: a population-based study. Can J Gastroenterol 24 (1):33–39Google Scholar
  52. 52.
    Allgar VL, Neal RD (2005) Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: cancer. Br J Cancer 92(11):1959–1970PubMedCrossRefGoogle Scholar
  53. 53.
    Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ (1997) Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112(2):594–642PubMedCrossRefGoogle Scholar
  54. 54.
    Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361(25):2449–2460PubMedCrossRefGoogle Scholar
  55. 55.
    Porta M, Fernandez E, Alguacil J (2003) Semiology, proteomics, and the early detection of symptomatic cancer. J Clin Epidemiol 56(9):815–819PubMedCrossRefGoogle Scholar
  56. 56.
    Singh H, Daci K, Petersen LA, Collins C, Petersen NJ, Shethia A, El-Serag HB (2009) Missed opportunities to initiate endoscopic evaluation for colorectal cancer diagnosis. Am J Gastroenterol 104(10):2543–2554PubMedCrossRefGoogle Scholar
  57. 57.
    McConnell YJ, Inglis K, Porter GA (2010) Timely access and quality of care in colorectal cancer: are they related? Int J Qual Health Care 22(3):219–228PubMedCrossRefGoogle Scholar
  58. 58.
    Rai S, Kelly MJ (2007) Prioritization of colorectal referrals: a review of the 2-week wait referral system. Colorectal Dis 9(3):195–202PubMedCrossRefGoogle Scholar
  59. 59.
    Siminoff LA, Rogers HL, Thomson MD, Dumenci L, Harris-Haywood S (2011) Doctor, what’s wrong with me? Factors that delay the diagnosis of colorectal cancer. Patient Educ Couns 84(3):352–358PubMedCrossRefGoogle Scholar
  60. 60.
    Hu CY, Delclos GL, Chan W, Du XL (2010) Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol 28(4):1062–1074Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Sandi L. Pruitt
    • 1
    • 2
  • Amy Jo Harzke
    • 3
  • Nicholas O. Davidson
    • 4
    • 5
  • Mario Schootman
    • 4
    • 6
  1. 1.Department of Clinical SciencesUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Harold C. Simmons Comprehensive Cancer CenterDallasUSA
  3. 3.Correctional Managed CareUniversity of Texas Medical BranchGalvestonUSA
  4. 4.Alvin J. Siteman Cancer Center at Barnes-Jewish HospitalWashington University School of MedicineSaint LouisUSA
  5. 5.Division of Gastroenterology, Department of MedicineWashington University School of MedicineSaint LouisUSA
  6. 6.Division of Health Behavior Research, Department of MedicineWashington University School of MedicineSaint LouisUSA

Personalised recommendations